首页> 美国卫生研究院文献>Cardiovascular Diabetology >Rationale design and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA®): a randomized double-blind placebo-controlled clinical trial in patients with type 2 diabetes and high cardio-renal risk

【2h】

Rationale design and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA®): a randomized double-blind placebo-controlled clinical trial in patients with type 2 diabetes and high cardio-renal risk

机译：LINAgliptin（CARMELINA®）进行的心血管安全性和肾脏微血管结果研究的基本原理设计和基线特征：一项针对2型糖尿病和高心脏肾脏风险患者的随机双盲安慰剂对照临床试验

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

BackgroundCardiovascular (CV) outcome trials in type 2 diabetes (T2D) have underrepresented patients with chronic kidney disease (CKD), leading to uncertainty regarding their kidney efficacy and safety. The CARMELINA^® trial aims to evaluate the effects of linagliptin, a DPP-4 inhibitor, on both CV and kidney outcomes in a study population enriched for cardio-renal risk.

机译：背景2型糖尿病（T2D）的心血管（CV）结果试验对慢性肾脏病（CKD）患者的代表性不足，导致其肾脏功效和安全性不确定。 CARMELINA ^{®试验旨在评估DPP-4抑制剂利格列汀对心肾风险丰富人群的CV和肾脏结局的影响。}

著录项

期刊名称 Cardiovascular Diabetology
作者
Julio Rosenstock; Vlado Perkovic; John H. Alexander; Mark E. Cooper; Nikolaus Marx; Michael J. Pencina; Robert D. Toto; Christoph Wanner; Bernard Zinman; David Baanstra; Egon Pfarr; Michaela Mattheus; Uli C. Broedl; Hans-Juergen Woerle; Jyothis T. George; Maximilian von Eynatten; Darren K. McGuire;
展开▼
作者单位

展开▼
年(卷),期 2018(17),-1
年度 2018
页码 39
总页数 15
原文格式 PDF
正文语种
中图分类心血管疾病;
关键词
Diabetes mellitus type 2; Cardiovascular diseases; Diabetic nephropathies; Dipeptidyl-peptidase IV inhibitors; Linagliptin; Clinical trial phase IV; Research design; Treatment outcome;

机译：2型糖尿病;心血管疾病;糖尿病肾病;二肽基肽酶IV抑制剂;利格列汀;临床试验;第四阶段;研究设计;治疗结果;

相似文献

外文文献
中文文献

1. Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA ? ): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high cardio-renal risk [J] . Julio Rosenstock, Vlado Perkovic, John H. Alexander, Cardiovascular Diabetology . 2018,第1期

机译：LINAgliptin（CARMELINA？）进行心血管安全性和肾脏微血管结果研究的基本原理，设计和基线特征：一项针对2型糖尿病和高心脏肾脏风险患者的随机，双盲，安慰剂对照临床试验
2. Harmony Outcomes: A randomized, double-blind, placebo-controlled trial of the effect of albiglutide on major cardiovascular events in patients with type 2 diabetes mellitus—Rationale, design, and baseline characteristics [J] . Jennifer B. Green, Adrian F. Hernandez, Ralph B. D’Agostino, The American heart journal . 2018,第期

机译：和谐结果：Athiglutide对2型糖尿病患者的患者主要心血管事件的随机，双盲，安慰剂对照试验，设计和基线特征
3. Effect of aspirin on renal disease progression in patients with type 2 diabetes: A multicenter, double-blind, placebo-controlled, randomized trial. The renaL disEase progression by aspirin in diabetic pAtients (LEDA) trial. Rationale and study design [J] . Violi Francesco, Targher Giovanni, Vestri Annarita, The American heart journal . 2017,第期

机译：阿司匹林对2型糖尿病患者肾病进展的影响：多中心，双盲，安慰剂，随机试验。阿司匹林在糖尿病患者（LEDA）试验中的肾病进展。理由和学习设计
4. Rationale, Design and Preliminary Results of ROMEO (Rethink Organization to Improve Education and Outcomes) A Randomized Controlled Multicenter Trial of Group Care in the Management ofType 1 Diabetes [C] . M. Porta, M. Trent European Association for the Study of Diabetes . 2005

机译：Romeo（重新思考组织改善教育和结果）的基本理由，设计和初步结果，在1型糖尿病的术语中进行了随机对照的组织的多中心试验
5. A Randomized, Double-blind, Placebo-controlled Clinical Trial Evaluating the Effect of Infliximab on General Cognition in a Population of Depressed Individuals with Bipolar Disorder Type I/II [D] . Pan, Zihang. 2018

机译：一项随机，双盲，安慰剂对照的临床试验，评估英夫利昔单抗对I / II型双相情感障碍抑郁症患者总体认知的影响
6. Rationale and design of the EMPA-ELDERLY trial: a randomised double-blind placebo-controlled 52-week clinical trial of the efficacy and safety of the sodium–glucose cotransporter-2 inhibitor empagliflozin in elderly Japanese patients with type 2 diabetes [O] . Daisuke Yabe, Kosuke Shiki, Keiko Suzaki, 2021

机译：Empa-Resion试验的理由和设计：随机双盲安慰剂控制52周的临床试验的钠葡萄糖Cotoransporter-2抑制剂Empagliflozin患者2型糖尿病患者的疗效和安全性
7. Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA®): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high cardio-renal risk [O] . Julio Rosenstock, Vlado Perkovic, John H. Alexander, 2018

机译：用Linagliptin（Carmelina®）的心血管安全性和肾微血管结果研究的基础，设计和基线特征：2型糖尿病患者的随机，双盲，安慰剂对照临床试验和高核心肾风险

Rationale design and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA®): a randomized double-blind placebo-controlled clinical trial in patients with type 2 diabetes and high cardio-renal risk

摘要

著录项

相似文献

相关主题

期刊订阅